Obesity Research - Health, Diet, Prevention, Exercise

Obesity Research Today is a free monthly online journal that collates and summarizes the latest research about Obesity, including details on health, diet, prevention, exercise.


Obesity Research Today

Home

View Latest Issue

Information About Obesity

Books on Obesity

Advertising in Research Today

View Other Research Today Publications



Effects of Momordica charantia on insulin resistance and visceral obesity in mice on high-fat diet.

Shih CC, Lin CH, Lin WL

Department of Nursing, College of Nursing, Central Taiwan University of Science and Technology, 11, Po-Tze Lane, Takun, Taichung, Taiwan, ROC. ccshih@ctust.edu.tw

We examined the preventive effect of Momordica charantia L. fruit (bitter melon) on hyperglycemia and insulin resistance in C57BL/6J mice fed with a high-fat (HF) diet. Firstly, mice were divided randomly into two groups: the control group was fed low-fat (LF) diet, whereas the experimental group was fed with a 45% HF diet last for 12 weeks. After 8 week of induction, the HF group was subdivided into six groups and was given orally with or without M. charantia or rosiglitazone 4 weeks afterward. We demonstrated that bitter melon was effective in ameliorating the HF diet-induced hyperglycemia, hyperleptinemia, and decreased the levels of blood glycated hemoglobin (HbA1c) and free fatty acid (FFA) (P<0.01, P<0.05, P<0.05, respectively), whereas increased the adipose PPARgamma and liver PPARalpha mRNA levels. Additionally, bitter melon significantly decreased the weights of epididymal white adipose tissue and visceral fat, and decreased the adipose leptin and resistin mRNA levels. It is tempting to speculate that at least a portion of bitter melon effects is due to be through PPARgamma-mediated pathways, resulting in lowering glucose levels and improving insulin resistance, and partly be through PPARalpha-mediated pathways to improve plasma lipid profiles. This is the first report demonstrating that bitter melon, is a food factor, but not a medicine, itself could influence dual PPARalpha/PPARgamma expression and the mediated gene expression, is effective in ameliorating insulin resistance and visceral obesity.

Published 28 July 2008 in Diabetes Res Clin Pract, 81(2): 134-43.
Full-text of this article is available online (may require subscription).

Place a permanent text-link or advertisement here for just US$15.

© 2004-2008 Obesity Research Today. All Rights Reserved.



Obesity Research Today Archive:

Volume 1 (2004)
  Issue 1 (September)
  Issue 2 (October)
  Issue 3 (November)
  Issue 4 (December)

Volume 2 (2005)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 3 (2006)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 4 (2007)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 5 (2008)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)



Obesity Books

Exodus from Obesity: The Guide to Long-Term Success After Weight Loss Surgery

Exodus from Obesity: The Guide to Long-Term Success After Weight Loss Surgery